Stock market volatility due to business interruptions caused by the novel coronavirus has brought most fundraising by public companies to a halt, but so far COVID-19 hasn’t slowed the flow of venture capital investment in biopharmaceutical companies with significant funding flowing to the industry, including financings announced on 1 April by iTeos Therapeutics SA, Pandion Therapeutics Inc. and Aspen Neuroscience.
Biotechnology stocks have performed better than broader stock indices since the COVID-19 pandemic forced companies globally across all industries to change the way they do business to stop the spread of the disease caused by the SARS-CoV-2 virus. Even so, biopharma stocks have seen double-digit declines, so perhaps privately held companies are a safer bet for investors until stock markets stabilize
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?